Upstream treatment of acute coronary syndrome in the ED

James D Kirk, Michael Kontos, Deborah B. Diercks

Research output: Contribution to journalArticle

Abstract

Rapid risk stratification, selection of downstream management options, and institution of initial pharmacotherapy are essential to ensure that patients admitted to the emergency department with acute coronary syndromes receive optimal care. A broad range of antiplatelet and antithrombotic medications is available that permits tailoring of initial pharmacotherapy to each patient's risk status. In the urgent setting, thienopyridines (clopidogrel and prasugrel) carry limitations including response variability and increased risk for bleeding in patients requiring subsequent coronary artery bypass graft surgery. Glycoprotein IIb-IIIa receptor inhibitors, although they are highly effective in preventing ischemic events, must be used with care to reduce bleeding risk. Bivalirudin, a relatively new direct thrombin inhibitor, represents another upstream option but is costly and does not have approval for this indication. Simplified institutional management paradigms can streamline the process of selecting appropriate pharmacotherapy and aid in care delivery that will optimize patient outcomes.

Original languageEnglish (US)
Pages (from-to)446-456
Number of pages11
JournalAmerican Journal of Emergency Medicine
Volume29
Issue number4
DOIs
StatePublished - May 2011

Fingerprint

Acute Coronary Syndrome
clopidogrel
Drug Therapy
Thienopyridines
Hemorrhage
Platelet Glycoprotein GPIIb-IIIa Complex
Antithrombins
Therapeutics
Coronary Artery Bypass
Hospital Emergency Service
Transplants

ASJC Scopus subject areas

  • Emergency Medicine

Cite this

Upstream treatment of acute coronary syndrome in the ED. / Kirk, James D; Kontos, Michael; Diercks, Deborah B.

In: American Journal of Emergency Medicine, Vol. 29, No. 4, 05.2011, p. 446-456.

Research output: Contribution to journalArticle

Kirk, James D ; Kontos, Michael ; Diercks, Deborah B. / Upstream treatment of acute coronary syndrome in the ED. In: American Journal of Emergency Medicine. 2011 ; Vol. 29, No. 4. pp. 446-456.
@article{85be042150d141c88e1a67142302bdd7,
title = "Upstream treatment of acute coronary syndrome in the ED",
abstract = "Rapid risk stratification, selection of downstream management options, and institution of initial pharmacotherapy are essential to ensure that patients admitted to the emergency department with acute coronary syndromes receive optimal care. A broad range of antiplatelet and antithrombotic medications is available that permits tailoring of initial pharmacotherapy to each patient's risk status. In the urgent setting, thienopyridines (clopidogrel and prasugrel) carry limitations including response variability and increased risk for bleeding in patients requiring subsequent coronary artery bypass graft surgery. Glycoprotein IIb-IIIa receptor inhibitors, although they are highly effective in preventing ischemic events, must be used with care to reduce bleeding risk. Bivalirudin, a relatively new direct thrombin inhibitor, represents another upstream option but is costly and does not have approval for this indication. Simplified institutional management paradigms can streamline the process of selecting appropriate pharmacotherapy and aid in care delivery that will optimize patient outcomes.",
author = "Kirk, {James D} and Michael Kontos and Diercks, {Deborah B.}",
year = "2011",
month = "5",
doi = "10.1016/j.ajem.2010.01.023",
language = "English (US)",
volume = "29",
pages = "446--456",
journal = "American Journal of Emergency Medicine",
issn = "0735-6757",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Upstream treatment of acute coronary syndrome in the ED

AU - Kirk, James D

AU - Kontos, Michael

AU - Diercks, Deborah B.

PY - 2011/5

Y1 - 2011/5

N2 - Rapid risk stratification, selection of downstream management options, and institution of initial pharmacotherapy are essential to ensure that patients admitted to the emergency department with acute coronary syndromes receive optimal care. A broad range of antiplatelet and antithrombotic medications is available that permits tailoring of initial pharmacotherapy to each patient's risk status. In the urgent setting, thienopyridines (clopidogrel and prasugrel) carry limitations including response variability and increased risk for bleeding in patients requiring subsequent coronary artery bypass graft surgery. Glycoprotein IIb-IIIa receptor inhibitors, although they are highly effective in preventing ischemic events, must be used with care to reduce bleeding risk. Bivalirudin, a relatively new direct thrombin inhibitor, represents another upstream option but is costly and does not have approval for this indication. Simplified institutional management paradigms can streamline the process of selecting appropriate pharmacotherapy and aid in care delivery that will optimize patient outcomes.

AB - Rapid risk stratification, selection of downstream management options, and institution of initial pharmacotherapy are essential to ensure that patients admitted to the emergency department with acute coronary syndromes receive optimal care. A broad range of antiplatelet and antithrombotic medications is available that permits tailoring of initial pharmacotherapy to each patient's risk status. In the urgent setting, thienopyridines (clopidogrel and prasugrel) carry limitations including response variability and increased risk for bleeding in patients requiring subsequent coronary artery bypass graft surgery. Glycoprotein IIb-IIIa receptor inhibitors, although they are highly effective in preventing ischemic events, must be used with care to reduce bleeding risk. Bivalirudin, a relatively new direct thrombin inhibitor, represents another upstream option but is costly and does not have approval for this indication. Simplified institutional management paradigms can streamline the process of selecting appropriate pharmacotherapy and aid in care delivery that will optimize patient outcomes.

UR - http://www.scopus.com/inward/record.url?scp=79955738041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955738041&partnerID=8YFLogxK

U2 - 10.1016/j.ajem.2010.01.023

DO - 10.1016/j.ajem.2010.01.023

M3 - Article

C2 - 20825856

AN - SCOPUS:79955738041

VL - 29

SP - 446

EP - 456

JO - American Journal of Emergency Medicine

JF - American Journal of Emergency Medicine

SN - 0735-6757

IS - 4

ER -